Aliases & Classifications for Hidradenitis

MalaCards integrated aliases for Hidradenitis:

Name: Hidradenitis 12 43 15 71
Hydradenitis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2282
ICD9CM 34 705.83
MeSH 43 D016575
NCIt 49 C112190
SNOMED-CT 67 69741000
UMLS 71 C0085160

Summaries for Hidradenitis

Disease Ontology : 12 A sweat gland disease that is characterized by inflammation of the apocrine sweat glands and has symptom erythema, edema, papules, plaques, pruritis, and pain.

MalaCards based summary : Hidradenitis, also known as hydradenitis, is related to dowling-degos disease and crohn's colitis, and has symptoms including erythema An important gene associated with Hidradenitis is NCSTN (Nicastrin), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Adalimumab and Spironolactone have been mentioned in the context of this disorder. Affiliated tissues include skin, neutrophil and breast, and related phenotypes are cellular and hematopoietic system

Related Diseases for Hidradenitis

Diseases related to Hidradenitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 675)
# Related Disease Score Top Affiliating Genes
1 dowling-degos disease 31.1 PSENEN NCSTN KRT14
2 crohn's colitis 31.0 TNF NOD2 IL1B IFNG
3 exanthem 30.8 TNF IL1B IFNG
4 pyoderma 30.7 TNF NOD2 IL1B DSG3 DSG1
5 keratitis, hereditary 30.6 TNF TLR4 IL1B IL17A
6 arthropathy 30.6 TNF LTA IL1B IFNG
7 brucellosis 30.5 TNF TLR4 IL17A IFNG
8 alopecia 30.5 TNF KRT14 IL1B IFNG
9 alopecia areata 30.4 TNF IL1B IL17A IFNG
10 spondyloarthropathy 30.4 TNF LTA IL1B IL17A IFNG
11 histiocytosis 30.4 TNF IL17A IFNG
12 spondylarthropathy 30.3 TNF TLR4 NOD2 LTA
13 filariasis 30.3 TNF TLR4 IFNG
14 bone inflammation disease 30.3 TNF TLR4 IL1B IL17A IFNG
15 necrotizing fasciitis 30.3 LTA IL1B CAMP
16 familial mediterranean fever 30.3 TNF TLR4 NOD2 IL1B IL17A
17 neutropenia 30.3 TNF TLR4 IL1B IFNG
18 fasciitis 30.3 TNF LTA IFNG
19 ulcerative colitis 30.3 TNF TLR4 NOD2 IL1B IL17A IFNG
20 spondylitis 30.2 TNF NOD2 LTA IL17A IFNG
21 pachyonychia congenita 1 30.2 KRT14 KRT10 DSG1
22 chorioretinitis 30.2 TNF IL17A IFNG
23 plague 30.1 TNF TLR4 IL1B
24 idiopathic neutropenia 30.1 TNF TLR4 IL1B
25 osteomyelitis 30.1 TNF TLR4 NOD2 IL1B IFNG
26 inflammatory bowel disease 1 30.1 TNF TLR4 NOD2
27 reactive arthritis 30.1 TNF TLR4 IL1B IL17A IFNG
28 complex regional pain syndrome 30.1 TNF IL1B IFNG
29 keratoconjunctivitis 30.1 TNF IL17A IFNG
30 crohn's disease 30.1 TNF TLR4 S100A9 NOD2 IL1B IL17A
31 leukemia, acute monocytic 30.1 TNF TLR4 IL1B
32 dermatitis 30.0 TNF NOD2 IL1B IL17A IFNG DSG1
33 posterior uveitis 30.0 TNF LTA IFNG
34 neuritis 30.0 TNF IL1B IFNG
35 optic neuritis 30.0 TNF LTA IL1B
36 colitis 29.9 TNF TLR4 NOD2 IL1B IL17A IFNG
37 mumps 29.9 TNF IL1B IFNG
38 common cold 29.9 TNF TLR4 IL1B IL17A
39 urethritis 29.9 TNF TLR4 IL1B CAMP
40 systemic scleroderma 29.9 TNF IL1B IL17A IFNG
41 hashimoto thyroiditis 29.9 TNF IL1B IL17A IFNG
42 chlamydia 29.8 TNF TLR4 IL1B IL17A IFNG
43 hyper ige syndrome 29.8 TNF TLR4 IL17A IFNG
44 food allergy 29.8 TNF TLR4 IL17A IFNG
45 candidiasis 29.8 TNF TLR4 IL1B IL17A IFNG
46 uveitis 29.8 TNF NOD2 LTA IL1B IL17A IFNG
47 monocytic leukemia 29.8 TNF TLR4 IL1B IFNG
48 viral hepatitis 29.8 TNF TLR4 IL1B IFNG
49 endocarditis 29.8 TNF KRT10 IL17A IFNG
50 pulmonary sarcoidosis 29.8 TNF LTA IL12RB1 IFNG

Graphical network of the top 20 diseases related to Hidradenitis:



Diseases related to Hidradenitis

Symptoms & Phenotypes for Hidradenitis

Symptoms:

12
  • erythema

MGI Mouse Phenotypes related to Hidradenitis:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.32 CAMP DSC1 DSG3 IFNG KRT14 KRT7
2 hematopoietic system MP:0005397 10.31 CAMP DSG3 IFNG IL12RB1 IL17A IL1B
3 growth/size/body region MP:0005378 10.3 DSC1 DSG1 DSG3 IFNG IL12RB1 IL17A
4 immune system MP:0005387 10.27 CAMP DSC1 DSG3 IFNG IL12RB1 IL17A
5 homeostasis/metabolism MP:0005376 10.25 DSC1 DSG3 IFNG IL12RB1 IL17A IL1B
6 craniofacial MP:0005382 10.15 DSC1 DSG3 IFNG IL17A IL1B KRT14
7 digestive/alimentary MP:0005381 10.13 DSG3 IFNG IL17A KRT14 NOD2 PIP
8 integument MP:0010771 10.1 DSC1 DSG1 DSG3 IFNG IL12RB1 IL17A
9 mortality/aging MP:0010768 10.1 CAMP DSG3 IFNG IL17A IL1B KRT14
10 respiratory system MP:0005388 9.76 DSG3 IFNG IL17A KRT14 LTA PSEN1
11 skeleton MP:0005390 9.65 DSG1 DSG3 IFNG IL17A IL1B LTA
12 vision/eye MP:0005391 9.36 CAMP DSC1 DSG1 DSG3 IFNG KRT14

Drugs & Therapeutics for Hidradenitis

Drugs for Hidradenitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 87)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Adalimumab Approved Phase 4 331731-18-1 16219006
2
Spironolactone Approved Phase 4 52-01-7, 1952-01-7 5833
3 Anesthetics Phase 4
4 Antirheumatic Agents Phase 4
5 Anti-Inflammatory Agents Phase 4
6 Potassium Supplement Phase 4
7 Anti-Bacterial Agents Phase 3
8 Antibiotics, Antitubercular Phase 3
9
Etanercept Approved, Investigational Phase 2 185243-69-0
10
Infliximab Approved Phase 2 170277-31-3
11
Ustekinumab Approved, Investigational Phase 2 815610-63-0
12
Apremilast Approved, Investigational Phase 2 608141-41-9 11561674
13
Hydroxychloroquine Approved Phase 1, Phase 2 118-42-3 3652
14 Brodalumab Approved, Investigational Phase 2 1174395-19-7
15
Upadacitinib Approved, Investigational Phase 2 1310726-60-3 58557659
16
Methylene blue Approved, Investigational Phase 2 61-73-4
17
Tofacitinib Approved, Investigational Phase 2 477600-75-2
18
Estradiol Approved, Investigational, Vet_approved Phase 2 50-28-2 5757
19
Drospirenone Approved Phase 2 67392-87-4 68873
20
Ethinyl Estradiol Approved Phase 2 57-63-6 5991
21
Polyestradiol phosphate Approved Phase 2 28014-46-2
22
Glutamic acid Approved, Nutraceutical Phase 2 56-86-0 33032
23 Gastrointestinal Agents Phase 2
24 Analgesics, Non-Narcotic Phase 2
25 Analgesics Phase 2
26 Immunosuppressive Agents Phase 2
27 Anti-Inflammatory Agents, Non-Steroidal Phase 2
28 Antibodies, Monoclonal Phase 2
29 Interleukin 1 Receptor Antagonist Protein Phase 2
30 Antiparasitic Agents Phase 1, Phase 2
31 Antiprotozoal Agents Phase 1, Phase 2
32 Antimalarials Phase 1, Phase 2
33 lysine Phase 2
34 Immunologic Factors Phase 2
35 Dermatologic Agents Phase 2
36 Immunoglobulins Phase 2
37 Antibodies Phase 2
38 Protein Kinase Inhibitors Phase 2
39 Janus Kinase Inhibitors Phase 2
40 Anti-Infective Agents Phase 2
41 Anti-Infective Agents, Local Phase 2
42
Gentian Violet Phase 2 14426-25-6 3468
43 Gentian Phase 2
44 Pharmaceutical Solutions Phase 2
45 Mitogens Phase 2
46 Olive Phase 2
47 chlorophyllin Phase 2
48 Epidiolex Phase 2
49 interferons Phase 2
50 Hormones Phase 2

Interventional clinical trials:

(show top 50) (show all 110)
# Name Status NCT ID Phase Drugs
1 A Phase 4, Double-blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Adalimumab Used in Conjunction With Surgery in Subjects With Moderate to Severe Hidradenitis Suppurativa Completed NCT02808975 Phase 4 Placebo;Adalimumab
2 Cost-effectiveness of Adalimumab With Adjuvant Surgery Versus Adalimumab Monotherapy in the Treatment of Hidradenitis Suppurativa' Recruiting NCT03221621 Phase 4 Adalimumab Injection
3 Spironolactone in the Treatment of Hidradenitis Suppurativa: A Prospective, Open-Label Proof-of-Concept and Dose-Ranging Study Not yet recruiting NCT04100083 Phase 4 Spironolactone 50 MG;Spironolactone 100mg;Spironolactone 200 mg
4 Hidradenitis Suppurativa Patients' Experience of Treatment With Adalimumab Not yet recruiting NCT04132388 Phase 4 Adalimumab
5 A Phase 3, Open-Label Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER (Open-Label Extension) Completed NCT01635764 Phase 3
6 A Phase 3 Multicenter, Open-label, Single Arm Study of the Safety and Efficacy of Adalimumab in Japanese Subjects With Moderate to Severe Hidradenitis Suppurativa Completed NCT02904902 Phase 3 adalimumab
7 A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER II Completed NCT01468233 Phase 3
8 A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER I Completed NCT01468207 Phase 3
9 A Randomized, Double-blind, Multicenter Study Assessing Short (16 Weeks) and Long-term Efficacy (up to 1 Year), Safety, and Tolerability of 2 Subcutaneous Secukinumab Dose Regimens in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (SUNRISE) Recruiting NCT03713632 Phase 3 Secukinumab
10 A Randomized, Double-blind, Multi-center Study Assessing Short (16 Weeks) and Long-term Efficacy (up to 1 Year), Safety, and Tolerability of 2 Subcutaneous Secukinumab Dose Regimens in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (SUNSHINE). Recruiting NCT03713619 Phase 3 secukinumab
11 A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to Demonstrate Long-term Efficacy, Safety and Tolerability in Subjects With Moderate to Severe Hidradenitis Suppurativa Recruiting NCT04179175 Phase 3 secukinumab
12 A Single Center Clinical Trial to Evaluate the Effect of Sclerotherapy on Fistulas and Sinus Tracts in Adult Patients With Hidradenitis Suppurativa Suspended NCT02805595 Phase 3 23.4% Hypertonic saline;Saline
13 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa Suspended NCT04242498 Phase 3 Bimekizumab
14 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa Suspended NCT04242446 Phase 3 Bimekizumab
15 To Determine The Efficacy Of A 1320nm Nd: YAG Nonablative Laser For Treatment of Hidradenitis Suppurativa Terminated NCT00367328 Phase 3
16 A Phase 2 Study of the Safety and Efficacy of Etanercept for the Therapy of Hydradenitis Suppurativa Completed NCT00329823 Phase 2 Etanercept sc 50mg per week for 12 weeks
17 A Phase 2, Open-Label, Single-Arm Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa Completed NCT03569371 Phase 2 INCB054707
18 A Randomized, Double-blind, Placebo Controlled, Multiple Dose Study to Evaluate the Clinical Efficacy, Safety, Tolerability, Dose Relation, Pharmacokinetics and Pharmacodynamics of CJM112 in Moderate to Severe Chronic Hidradenitis Suppurativa Patients Completed NCT02421172 Phase 2 Placebo
19 Phase 2 Study to Assess the Safety and Efficacy of Infliximab for the Treatment of Hidradenitis Suppurativa Completed NCT00795574 Phase 2 infliximab;Placebo Comparator
20 A Phase 2, Dose-Escalation, Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa Completed NCT03607487 Phase 2 INCB054707;Placebo
21 A Phase 2 Multicenter, Investigator-Blind, Subject-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa Completed NCT03248531 Phase 2 Bimekizumab;Adalimumab
22 Open Label,Phase Two Study to Assess the Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa Completed NCT00827996 Phase 2 adalimumab
23 A Prospective Proof of Concept Study to Evaluate the Potential Efficacy of Ustekinumab in Patients With Moderate to Severe Hidradenitis Suppurativa (Acne Ectopica) Completed NCT01704534 Phase 2 Ustekinumab
24 An Open Label Phase II Trial to Evaluate the Safety of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa Completed NCT03001622 Phase 2
25 An Open Label Non-randomized Study Assessing the Efficacy and Tolerability of Fixed-dose Regimen Daily Subcutaneous Anakinra for the Treatment of Moderate to Severe Hidradenitis Suppurativa Completed NCT01516749 Phase 2 anakinra
26 A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Determine Efficacy and Safety of IFX-1 in Subjects With Moderate to Severe Hidradenitis Suppurativa Completed NCT03487276 Phase 2 IFX-1;Placebo
27 A Phase II, Open Label Study of Bermekimab in Patients With Moderate to Severe Hidradenitis Suppurativa Completed NCT03512275 Phase 2 Bermekimab Monoclonal Antibody 400 mg
28 A Phase II Open Label Clinical Trial of Etanercept for the Treatment of Hidradenitis Suppurativa Completed NCT00107991 Phase 2 etanercept
29 Short-term Safety, Efficacy and Mode of Action of Apremilast in Moderate Suppurative Hidradenitis: A Randomised Double-blind Placebo Controlled Trial Completed NCT03049267 Phase 2 Apremilast;Placebo Oral Tablet
30 A Phase 2 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa Completed NCT00918255 Phase 2 Placebo
31 A Phase 2 Open-label Single Center Study to Evaluate the Efficacy of Apremilast for the Treatment of Moderate Hidradenitis Suppurativa Completed NCT02695212 Phase 2 Apremilast
32 A Double-blind, Randomized, Placebo-controlled Clinical Trial of the Safety and Efficacy of Anakinra in Patients With Hidradenitis Suppurativa Completed NCT01558375 Phase 2 Water for injection;Anakinra
33 Pilot Study of Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa Completed NCT03275870 Phase 1, Phase 2 Hydroxychloroquine
34 A Double-blind, Randomised, Placebo-controlled Clinical Trial of the Efficacy of MABp1, a- First-in-class True Human Antibody Targeting Interleukin-1alpha, in Patients With Hidradenitis Suppurativa Not Eligible for antiTNF Therapy Completed NCT02643654 Phase 2 MABp1;Placebo
35 A Randomized, Subject and Investigator Blinded, Placebo-controlled and Multi-center Platform Study, to Assess Efficacy and Safety of Different Investigational Drugs in Patients With Moderate to Severe Hidradenitis Suppurativa Recruiting NCT03827798 Phase 2 CFZ533;Placebo to CFZ533;LYS006;Placebo to LYS006
36 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Risankizumab in Adult Subjects With Moderate to Severe Hidradenitis Suppurativa Recruiting NCT03926169 Phase 2 Risankizumab;Placebo for risankizumab
37 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa Recruiting NCT03852472 Phase 2 Avacopan
38 A PHASE 2A, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 16-WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF PF-06650833, PF-06700841, AND PF-06826647 IN ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA Recruiting NCT04092452 Phase 2 PF-06650833;PF-06700841;PF-06826647;Placebo
39 Clinical Efficacy of Inhibition of Organ Dysfunction Through Bermekimab in Systemic Sclerosis: A Proof- Of-Concept Double-Blind Randomized Clinical Trial (the Light Trial) Recruiting NCT04045743 Phase 2 MABp1 (Bermekimab) OR Placebo;MABp1 (Bermekimab)
40 A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients With Moderate to Severe Hidradenitis Suppurativa Active, not recruiting NCT04019041 Phase 2 bermekimab;placebo
41 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects With Moderate to Severe Hidradenitis Suppurativa Active, not recruiting NCT03628924 Phase 2 Guselkumab dose 1;Guselkumab dose 2;Guselkumab dose 3;Placebo
42 Guselkumab for Hidradenitis Suppurativa, a Mode of Action Study. The HiGUS-trial Not yet recruiting NCT04061395 Phase 2
43 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adult Subjects With Moderate to Severe Hidradenitis Suppurativa Not yet recruiting NCT04430855 Phase 2 Upadacitinib;Placebo Upadacitinib
44 Effects of Gentian Violet Treatment on Patients With Hidradenitis Suppurativa Not yet recruiting NCT04388163 Phase 2 Gentian Violet
45 Exploratory Trial of Ruxolitinib 1.5% Cream for Early Stage Hidradenitis Suppurativa Not yet recruiting NCT04414514 Phase 2 Ruxolitinib 1.5% Cream
46 Prospective Case Series on a Combination Methylene Blue, Gentian Violet, and Ovine Forestomach-derived Extracellular Matrix Dressing for Hidradenitis Suppurativa Not yet recruiting NCT04354012 Phase 2
47 A Phase Ⅱ, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabis Oil for the Treatment of Subjects With Hidradenitis Suppurativa Not yet recruiting NCT03929835 Phase 2 Cannabis oil;Placebo
48 An Open-label Single Center Study to Evaluate the Efficacy of SILIQ™ (Brodalumab) for the Treatment of Moderate Hidradenitis Suppurativa Not yet recruiting NCT03910803 Phase 2 Brodalumab
49 Safety and Efficacy of Tofacitinib for Immune Skin Conditions in Down Syndrome Not yet recruiting NCT04246372 Phase 2 Tofacitinib
50 A Phase IIa Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability and Preliminary Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa Terminated NCT01838499 Phase 2

Search NIH Clinical Center for Hidradenitis

Cochrane evidence based reviews: hidradenitis

Genetic Tests for Hidradenitis

Anatomical Context for Hidradenitis

MalaCards organs/tissues related to Hidradenitis:

40
Skin, Neutrophil, Breast, Liver, Testes, Colon, Myeloid

Publications for Hidradenitis

Articles related to Hidradenitis:

(show top 50) (show all 2888)
# Title Authors PMID Year
1
Factors affecting quality of life in patients with hidradenitis suppurativa. 61
31848682 2020
2
Hidradenitis suppurativa on Facebook: thematic and content analyses of patient support group. 61
31845011 2020
3
Pyoderma gangrenosum and suppurative hidradenitis association, overlap or spectrum of the same disease? Case report and discussion. 61
32508990 2020
4
Hidradenitis suppurativa: The importance of virtual outpatient care during COVID-19 pandemic. 61
32360857 2020
5
Adalimumab for treatment of hidradenitis suppurativa during the COVID-19 pandemic: Safety considerations. 61
32283230 2020
6
Hidradenitis suppurativa management using tumor necrosis factor inhibitors in patients younger than 18 years: A series of 12 cases. 61
32151626 2020
7
Conversion to positive latent tuberculosis infection status is low in patients with hidradenitis suppurativa taking biologic medications. 61
31940465 2020
8
Response to Ring et al.: In Silico Predictive Metagenomic Analyses Highlight Key Metabolic Pathways Impacted in the Hidradenitis Suppurativa Skin Microbiome. 61
32088206 2020
9
Description of a disease activity proforma for documentation of hidradenitis suppurativa severity and distribution, and suggestions for use as a patient-reported outcome measure. 61
31885089 2020
10
Predictive Metagenomic Analysis Reveals a Role of Cutaneous Dysbiosis in the Development of Hidradenitis Suppurativa. 61
31838125 2020
11
Lesional Inflammatory Profile in Hidradenitis Suppurativa Is Not Solely Driven by IL-1. 61
32081612 2020
12
Ex Vivo Models and Interpretation of Mechanistic Studies in Hidradenitis Suppurativa. 61
32571498 2020
13
Amyloidosis in hidradenitis suppurativa: a cross-sectional study and review of the literature. 61
31989656 2020
14
Successful use of guselkumab in the treatment of severe hidradenitis suppurativa. 61
32068912 2020
15
Support group utilization and impact for patients with hidradenitis suppurativa. 61
31541749 2020
16
Remote management of hidradenitis suppurativa in a pandemic era of COVID-19. 61
32578210 2020
17
Is biologic treatment of hidradenitis suppurativa during the COVID-19 pandemic different from psoriasis biologic treatment? 61
32432955 2020
18
Management of patients with Hidradenitis Suppurativa during the COVID-19 pandemic. 61
32558071 2020
19
Male granulomatous mastitis with hidradenitis suppurativa, a rarely encountered disorder. 61
32515519 2020
20
Sexual impairment in patients with hidradenitis suppurativa: a systematic review. 61
32531099 2020
21
Hidradenitis suppurativa and risk for development of Clostridium difficile colitis. 61
32010962 2020
22
Hidradenitis Suppurativa and Crohn Disease: A Rare Association. 61
32304573 2020
23
A case of Atopic dermatitis and Hidradenitis Suppurativa successfully treated with Dupilumab. 61
32034813 2020
24
Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic. 61
32277351 2020
25
The Use of TNFα Inhibitors in Treating Pediatric Skin Disorders. 61
32350817 2020
26
Cellulitis-like Sweet Syndrome caused by adalimumab therapy for severe hidradenitis suppurativa. 61
32567672 2020
27
Hidradenitis suppurativa in a long-lived patient with trisomy 13. 61
32490117 2020
28
Hidradenitis Suppurativa is Associated with Symptoms of Keratoconjunctivitis Sicca. 61
32506959 2020
29
Topical antibiotics in the dermatological clinical practice: indications, efficacy and adverse effects. 61
32531105 2020
30
Immunomodulatory Drugs Alone and Adjuvant to Surgery for Hidradenitis Suppurativa/ Acne Inversa - A Narrative Review. 61
32558202 2020
31
Spironolactone in Dermatology: Uses in Acne, Hidradenitis Suppurativa, Female Pattern Baldness, and Hirsutism. 61
32571540 2020
32
Further evidence for the immediate knowledge improvement through EADV Schools on hidradenitis suppurativa / acne inversa. 61
32535980 2020
33
A network analysis of the EADV 2019 conference. 61
32485060 2020
34
Clinical response rate and flares of hidradenitis suppurativa in the treatment with adalimumab. 61
31630436 2020
35
Treatment of hidradenitis suppurativa: Surgery and yeast (Saccharomyces cerevisiae)-exclusion diet. Results after 6 years. 61
32098690 2020
36
Risk of connective tissue disease, morphea and systemic vasculitis in patients with hidradenitis suppurativa. 61
32531094 2020
37
Hidradenitis Suppurativa and Concurrent Psoriasis: Comparison of Epidemiology, Comorbidity Profiles, and Risk Factors. 61
32500484 2020
38
Dermatologic conditions in Down syndrome: A single-center retrospective chart review. 61
32519435 2020
39
Pleiotropic Role of Notch Signaling in Human Skin Diseases. 61
32545758 2020
40
Polyclonal gammopathy in an adolescent affected by Dent disease 2 and hidradenitis suppurativa. 61
31971248 2020
41
What counts? The relationship between patient estimated numbers of painful HS lesions over four weeks compared with clinician's lesion count at the time of examination. 61
32488900 2020
42
Association of retinol binding protein 4 (RBP4) and ghrelin plasma levels with insulin resistance and disease severity in non-diabetic patients with Hidradenitis suppurativa. 61
32564394 2020
43
Efficacy of topical Ichthammol 10% for Hidradenitis Suppurativa: case series and systematic review of its use in dermatology. 61
32558051 2020
44
Baseline patient-reported outcomes from UNITE: an observational, international, multicentre registry to evaluate hidradenitis suppurativa in clinical practice. 61
31800124 2020
45
Reconstruction for axillary hidradenitis suppurativa using one-stage local tissue rearrangement: A retrospective analysis of 53 cases. 61
32067416 2020
46
Photobiomodulation therapy is able to decrease IL1B gene expression in an in vitro cellular model of hidradenitis suppurativa. 61
31444612 2020
47
The contradictory inefficacy of methotrexate in hidradenitis suppurativa: a need to revise pathogenesis or acknowledge disease heterogeneity? 61
30945961 2020
48
MABp1 targeting interleukin-1alpha in hidradenitis suppurativa non-eligible for adalimumab treatment: Results of the open-label extension period. 61
32516832 2020
49
Effect of Hidradenitis Suppurativa Disease Duration on Psychiatric Comorbidity. 61
32556339 2020
50
Moderate to Severe Hidradenitis Suppurativa Successfully Treated With Secukinumab. 61
32553985 2020

Variations for Hidradenitis

Expression for Hidradenitis

Search GEO for disease gene expression data for Hidradenitis.

Pathways for Hidradenitis

Pathways related to Hidradenitis according to GeneCards Suite gene sharing:

(show all 48)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.87 TNF TLR4 S100A9 PSEN1 NOD2 NCSTN
2
Show member pathways
13.82 TNF PSENEN PSEN1 PIP NCSTN LTA
3
Show member pathways
13.46 TNF PSENEN NCSTN KRT7 KRT14 KRT10
4
Show member pathways
13.35 TNF NOD2 LTA IL1B IL17A IL12RB1
5
Show member pathways
13.21 TNF TLR4 PSENEN PSEN1 NCSTN IL1B
6
Show member pathways
12.84 TNF LTA IL1B IL17A IFNG
7
Show member pathways
12.58 TNF TLR4 IL1B IL17A IFNG
8
Show member pathways
12.56 TNF IL1B IL17A IL12RB1 IFNG
9
Show member pathways
12.41 KRT7 KRT14 KRT10 DSG3 DSG1 DSC1
10
Show member pathways
12.34 TNF TLR4 NOD2 IL1B IL17A IL12RB1
11
Show member pathways
12.3 TNF TLR4 IL1B IFNG
12
Show member pathways
12.28 TNF S100A9 IL1B IL17A IFNG
13
Show member pathways
12.26 TNF TLR4 IL1B IFNG
14
Show member pathways
12.25 TNF LTA IL1B IL17A IFNG
15
Show member pathways
12.2 TNF TLR4 IL1B IFNG
16
Show member pathways
12.18 TNF TLR4 IL1B IFNG
17 12.18 TNF TLR4 NOD2 IL1B CAMP
18 12.08 TNF PSENEN PSEN1 NCSTN IL1B
19 12 TNF TLR4 IL1B IFNG
20 11.96 TNF NOD2 LTA IL1B
21 11.91 TNF TLR4 LTA IL1B
22 11.89 TNF TLR4 IL1B IFNG
23 11.89 TNF TLR4 NOD2 IL1B IFNG CAMP
24 11.85 KRT14 KRT10 DSG1 CAMP
25 11.75 TNF TLR4 IL1B
26 11.74 TNF IL1B IFNG
27 11.73 TNF TLR4 IL1B IL17A IFNG
28
Show member pathways
11.68 PSENEN PSEN1 NCSTN
29
Show member pathways
11.68 TLR4 IL1B IL17A IL12RB1 IFNG
30
Show member pathways
11.66 TNF IL1B IFNG
31 11.61 TNF TLR4 IL1B
32 11.58 TNF TLR4 LTA
33
Show member pathways
11.55 TNF LTA IFNG
34 11.51 TNF IL1B IFNG
35 11.49 PSENEN PSEN1 NCSTN
36 11.49 TNF TLR4 IL1B IFNG
37 11.48 TNF IL1B IFNG
38 11.44 TNF TLR4 IL1B IFNG
39 11.37 TNF IL1B IFNG
40 11.34 TNF TLR4 IL1B
41 11.34 TNF LTA IL1B IL17A IL12RB1 IFNG
42 11.25 TNF IL1B IFNG
43 11.21 TNF IL1B IL17A IFNG
44
Show member pathways
11.19 TNF TLR4 LTA IL1B IL17A IL12RB1
45 11.15 S100A9 IL1B IFNG
46 11.1 PSENEN PSEN1 NCSTN
47 10.94 PSENEN PSEN1 NCSTN
48 10.36 PSENEN PSEN1

GO Terms for Hidradenitis

Cellular components related to Hidradenitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.02 TNF S100A9 PIP LTA KRT10 IL1B
2 extracellular exosome GO:0070062 9.97 S100A9 PIP NCSTN KRT7 KRT14 KRT10
3 extracellular space GO:0005615 9.91 TNF S100A9 PIP LTA KRT10 IL1B
4 desmosome GO:0030057 9.33 DSG3 DSG1 DSC1
5 cornified envelope GO:0001533 9.26 KRT10 DSG3 DSG1 DSC1
6 gamma-secretase complex GO:0070765 8.8 PSENEN PSEN1 NCSTN

Biological processes related to Hidradenitis according to GeneCards Suite gene sharing:

(show top 50) (show all 64)
# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 10.18 S100A9 PSEN1 LTA IL1B IL17A IFNG
2 immune response GO:0006955 10.15 TNF TLR4 LTA IL1B IL17A IFNG
3 positive regulation of gene expression GO:0010628 10.15 TNF TLR4 PSEN1 PIP IL1B IFNG
4 neutrophil degranulation GO:0043312 10.14 S100A9 PSEN1 NCSTN DSG1 DSC1 CAMP
5 inflammatory response GO:0006954 10.1 TNF TLR4 S100A9 IL1B IL17A
6 positive regulation of apoptotic process GO:0043065 10.1 TNF PSENEN PSEN1 NCSTN LTA
7 defense response to bacterium GO:0042742 10.07 TNF TLR4 S100A9 NOD2 CAMP
8 cell-cell signaling GO:0007267 10.03 S100A9 LTA IL1B IL17A
9 positive regulation of protein phosphorylation GO:0001934 10.02 TNF PSEN1 IL1B IFNG CAMP
10 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 10.01 TNF TLR4 NOD2 IL1B
11 cellular response to lipopolysaccharide GO:0071222 10.01 TNF TLR4 NOD2 IL1B CAMP
12 cell-cell adhesion GO:0098609 10 PSEN1 DSG3 DSG1 DSC1
13 activation of MAPK activity GO:0000187 9.98 TNF TLR4 NOD2 IL1B
14 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.98 TNF TLR4 S100A9 NOD2 IL1B
15 regulation of inflammatory response GO:0050727 9.94 TNF TLR4 S100A9 NOD2
16 positive regulation of JNK cascade GO:0046330 9.94 TNF TLR4 NOD2 IL1B
17 ephrin receptor signaling pathway GO:0048013 9.91 PSENEN PSEN1 NCSTN
18 keratinization GO:0031424 9.91 KRT7 KRT14 KRT10 DSG3 DSG1 DSC1
19 regulation of insulin secretion GO:0050796 9.9 TNF IL1B IFNG
20 cellular response to organic cyclic compound GO:0071407 9.9 TNF NOD2 IL1B
21 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.9 TNF TLR4 NOD2 IL1B
22 positive regulation of MAP kinase activity GO:0043406 9.89 TNF PSEN1 NOD2
23 protein processing GO:0016485 9.89 PSENEN PSEN1 NCSTN
24 humoral immune response GO:0006959 9.89 TNF LTA IFNG
25 positive regulation of interleukin-6 production GO:0032755 9.88 TNF TLR4 NOD2 IL1B
26 positive regulation of inflammatory response GO:0050729 9.88 TNF TLR4 S100A9 IL1B IFNG
27 positive regulation of phagocytosis GO:0050766 9.86 TNF IL1B IFNG
28 lipopolysaccharide-mediated signaling pathway GO:0031663 9.86 TNF TLR4 IL1B
29 positive regulation of osteoclast differentiation GO:0045672 9.83 TNF IL17A IFNG
30 positive regulation of nitric oxide biosynthetic process GO:0045429 9.83 TNF TLR4 IL1B IFNG
31 membrane protein ectodomain proteolysis GO:0006509 9.82 PSENEN PSEN1 NCSTN
32 positive regulation of glial cell proliferation GO:0060252 9.81 TNF LTA IL1B
33 membrane protein intracellular domain proteolysis GO:0031293 9.8 PSENEN PSEN1 NCSTN
34 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.79 TNF IL1B IFNG
35 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.78 TLR4 NOD2 IFNG
36 positive regulation of chemokine biosynthetic process GO:0045080 9.77 TNF IL1B IFNG
37 positive regulation of interleukin-8 production GO:0032757 9.76 TNF TLR4 NOD2 IL1B
38 amyloid precursor protein metabolic process GO:0042982 9.74 PSENEN PSEN1 NCSTN
39 positive regulation of chemokine (C-X-C motif) ligand 2 production GO:2000343 9.73 TNF TLR4
40 positive regulation of neuroinflammatory response GO:0150078 9.73 TNF IL1B
41 negative regulation of amyloid-beta clearance GO:1900222 9.73 TNF IFNG
42 positive regulation of MHC class II biosynthetic process GO:0045348 9.73 TLR4 IFNG
43 amyloid precursor protein catabolic process GO:0042987 9.73 PSENEN PSEN1 NCSTN
44 regulation of establishment of endothelial barrier GO:1903140 9.72 TNF IL1B
45 positive regulation of interleukin-12 biosynthetic process GO:0045084 9.72 TLR4 IL17A
46 Notch receptor processing GO:0007220 9.72 PSENEN PSEN1 NCSTN
47 cellular response to peptidoglycan GO:0071224 9.71 NOD2 CAMP
48 positive regulation of interleukin-1 beta biosynthetic process GO:0050725 9.71 TNF IL17A IFNG
49 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.71 TNF TLR4 NOD2 IL17A
50 positive regulation of interleukin-23 production GO:0032747 9.7 IL17A IFNG

Molecular functions related to Hidradenitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.91 TNF TLR4 S100A9 PSENEN PSEN1 PIP
2 growth factor receptor binding GO:0070851 9.16 PSEN1 NCSTN
3 cytokine activity GO:0005125 9.02 TNF LTA IL1B IL17A IFNG

Sources for Hidradenitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....